Philip S. Low
Next Generation Targeted Therapeutics
Companies Founded
Founder and chief science officer
Founder, chief science officer since 1998 and member of the Board of Directors since 1995 (purchased by Novartis in 2018 for $2.1 Billion USD)

Founder of Novosteo (now part of Quince Therapeutics)
Co-founder, raised over 270 million USD in 2021
Co-founder of Morphimmune (now part of Immunome)
Co-founder
Co-founder